Antihypertensive combination therapy: optimizing blood pressure control and cardiovascular risk reduction.

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Treating hypertension reduces the rates of myocardial infarction, stroke, and renal disease; however, clinical trial experience suggests that monotherapy is not likely to be successful for achieving goal blood pressure (BP) levels in many hypertensive patients. In multiple recent clinical trials including various subsets of hypertensive patients, the achievement of BP goal has typically required the combination of 2 or more medications, particularly in patients with BP levels>160/100 mm Hg. When initiating combination therapy for hypertension, careful consideration must be given to the choice of medication. Clinical trial evidence has shown the efficacy of various combinations of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium channel blockers, and diuretics in reducing BP and cardiovascular risk. Ongoing trials should provide additional guidance on the optimal choice of combination regimens in specific clinical settings.

Original languageEnglish (US)
Pages (from-to)26-32
Number of pages7
JournalJournal of clinical hypertension (Greenwich, Conn.)
Volume9
Issue number11 Suppl 4
StatePublished - Nov 2007

Fingerprint

Risk Reduction Behavior
Antihypertensive Agents
Blood Pressure
Clinical Trials
Hypertension
Angiotensin Receptor Antagonists
Calcium Channel Blockers
Therapeutics
Angiotensin-Converting Enzyme Inhibitors
Diuretics
Stroke
Myocardial Infarction
Kidney

ASJC Scopus subject areas

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

@article{e2a26a9a8fb34376bd5decacf6978212,
title = "Antihypertensive combination therapy: optimizing blood pressure control and cardiovascular risk reduction.",
abstract = "Treating hypertension reduces the rates of myocardial infarction, stroke, and renal disease; however, clinical trial experience suggests that monotherapy is not likely to be successful for achieving goal blood pressure (BP) levels in many hypertensive patients. In multiple recent clinical trials including various subsets of hypertensive patients, the achievement of BP goal has typically required the combination of 2 or more medications, particularly in patients with BP levels>160/100 mm Hg. When initiating combination therapy for hypertension, careful consideration must be given to the choice of medication. Clinical trial evidence has shown the efficacy of various combinations of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium channel blockers, and diuretics in reducing BP and cardiovascular risk. Ongoing trials should provide additional guidance on the optimal choice of combination regimens in specific clinical settings.",
author = "Nesbitt, {Shawna D.}",
year = "2007",
month = "11",
language = "English (US)",
volume = "9",
pages = "26--32",
journal = "Journal of clinical hypertension",
issn = "0895-7061",
publisher = "Oxford University Press",
number = "11 Suppl 4",

}

TY - JOUR

T1 - Antihypertensive combination therapy

T2 - optimizing blood pressure control and cardiovascular risk reduction.

AU - Nesbitt, Shawna D.

PY - 2007/11

Y1 - 2007/11

N2 - Treating hypertension reduces the rates of myocardial infarction, stroke, and renal disease; however, clinical trial experience suggests that monotherapy is not likely to be successful for achieving goal blood pressure (BP) levels in many hypertensive patients. In multiple recent clinical trials including various subsets of hypertensive patients, the achievement of BP goal has typically required the combination of 2 or more medications, particularly in patients with BP levels>160/100 mm Hg. When initiating combination therapy for hypertension, careful consideration must be given to the choice of medication. Clinical trial evidence has shown the efficacy of various combinations of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium channel blockers, and diuretics in reducing BP and cardiovascular risk. Ongoing trials should provide additional guidance on the optimal choice of combination regimens in specific clinical settings.

AB - Treating hypertension reduces the rates of myocardial infarction, stroke, and renal disease; however, clinical trial experience suggests that monotherapy is not likely to be successful for achieving goal blood pressure (BP) levels in many hypertensive patients. In multiple recent clinical trials including various subsets of hypertensive patients, the achievement of BP goal has typically required the combination of 2 or more medications, particularly in patients with BP levels>160/100 mm Hg. When initiating combination therapy for hypertension, careful consideration must be given to the choice of medication. Clinical trial evidence has shown the efficacy of various combinations of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium channel blockers, and diuretics in reducing BP and cardiovascular risk. Ongoing trials should provide additional guidance on the optimal choice of combination regimens in specific clinical settings.

UR - http://www.scopus.com/inward/record.url?scp=38449114700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38449114700&partnerID=8YFLogxK

M3 - Article

C2 - 17978604

AN - SCOPUS:38449114700

VL - 9

SP - 26

EP - 32

JO - Journal of clinical hypertension

JF - Journal of clinical hypertension

SN - 0895-7061

IS - 11 Suppl 4

ER -